There was an accidental death of BALB/c mice in the course of the experiment about hepatitis B immunization. The reasons of the mice breeding failure were analyzed in order to provide some experience for future animal preparation about hepatitis B immunization. Items of all mice including sex, age, dose of hepatitis B vaccine (HepBVac), dose of hepatitis B immunoglobulin (HBIG), immunization route, vaccination schedule and the acclimatization period were recorded before the first immunization. Among 334 mice included, the survival rates in different groups of initial ages were 45.9% in 3-week-old, 49.3% in 4-week-old, 51.9% in 5-week-old, 84.8% in 7-week-old and 96.6% in 8week-old; the survival rate in seven days acclimatization group was 96.6% and 53.3% in one day acclimatization group. Multivariate logistic regression analysis indicated that smaller ages (3 weeks, 4 weeks) and acclimatization for only one day were the independent risk factors affecting the survival of mice. Multivariate logistic regression analysis showed that injection with HBIG, lower dose of HepBVac and hypodermic injection were independent risk factors for low-and non-response to HepB Vac. It is suggested that the mice should be more than five-week-old and must have acclimated to the environment for one week before the experiment begins. The initial ages of the mice have no impact on their immune efficacy.
Background: Whether maternal anti-HBs acquired transplacentally plays a negative role in newborn infants’ immune response to hepatitis B vaccine (HepB Vac), it remains controversial and has not been paid enough attention.Methods: 267 BALB/c mice were bred. All mice were divided into two groups according to different doses of HepB Vac (2μg, 5μg) injected to mice. Each group was sub-divided into three subgroups according to different doses of hepatitis B immunoglobulin (HBIG) (50 IU, 25 IU, 0 IU) injected combined with the first dose of HepB Vac. Three doses of HepB Vac were administrated at 0 week, 4week and 8 week respectively. Antibodies against hepatitis B surface antigen (anti-HBs) were tested four weeks after the third dose of HepB Vac.Results: Among 267 mice, 40 were of low- and non-response to HepB Vac (anti-HBs<100 mIU/mL). Multivariate logistic regression analysis showed that rates of anti-HBs<100 mIU/mL were: 1.1%, 23.1% and 20.7% in groups of HBIG=0 IU(1), HBIG=25 IU(2) and HBIG=50 IU(3) respectively, p = 0.002, and among subgroups, (1) vs (3), RR= 0.032, 95% CI [0.004, 0.255], p = 0.001, (2) vs (3), RR= 1.359, 95% CI [0.588, 3.144], p = 0.473; 4.5% and 25.6% in groups of HepB Vac 5μg and 2μg, RR=0.093, 95% CI [0.035, 0.250], p <0.001; 6.1% and 23.7% in groups of intramuscular injection and hypodermic injection, RR=0.139, 95% CI [0.056, 0.346], p <0.001. The mean titers of anti-HBs (log10mIU/m) were on the decrease in turn in groups of HBIG= 0 IU, HBIG= 25 IU and HBIG= 50 IU, p <0.001.Conclusions: HBIG has a negative impact on both the rate of effective immune response and response level of anti-HBs, which preliminarily indicates maternal anti-HBs inhibits infants’ immune response to HepB Vac.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.